<DOC>
	<DOCNO>NCT01686334</DOCNO>
	<brief_summary>The primary aim innovative immunotherapeutic study determine whether antileukemic effect see previous phase I/II study confirm large cohort patient whether dendritic cell vaccination significantly prevent relapse increase survival AML patient eradicate minimal residual disease .</brief_summary>
	<brief_title>Efficacy Study Dendritic Cell Vaccination Patients With Acute Myeloid Leukemia Remission</brief_title>
	<detailed_description>Together Transplant Committee Belgian Hematological Society ( BHS ) , perform multicenter randomize open-label phase II clinical study 138 patient acute myeloid leukemia ( AML ) . Patients older 65 year complete hematological remission randomize vaccinated dendritic cell receive regular follow-up care . The primary aim innovative immunotherapeutic study determine whether antileukemic effect see previous phase I/II study confirm large cohort patient whether dendritic cell vaccination significantly prevent relapse increase survival AML patient eradicate minimal residual disease . Patients recruit 8 different center Belgium . Recruitment start second half 2012 last three year 138 efficacy-evaluable AML patient include . In interventional group , 69 patient treat two year autologous dendritic cell load messenger RNA electroporation Wilms ' tumor antigen ( WT1 ) . The dendritic cell therapy product generate generally administer coordinating center , Antwerp University Hospital , specifically Center Cell Therapy Regenerative Medicine ( CCRG ) Division Hematology , head Prof. Zwi Berneman . After inclusion 138 efficacy-evaluable patient , relapse rate , relapse-free survival overall survival analysis perform . Tumor marker level immune activation also monitor compare 2 group molecular immunological level .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosis acute myeloid leukemia ( AML ) accord 2008 criteria World Health Organization ( WHO ) .18 FrenchAmericanBritish ( FAB ) subtypes , except : M3 ( acute promyelocytic leukemia ) case de novo AML secondary AML ≥ 20 % blast peripheral blood and/or bone marrow , except : AML secondary myeloproliferative neoplasm ( MPN ) AML secondary exposure leukemogenic agent ( tAML ) . WT1 transcript level peripheral blood and/or bone marrow increase background time diagnosis , determine qRTPCR . Completion least one cycle induction chemotherapy one cycle consolidation chemotherapy result : morphological complete remission ( CR ) , i.e . bone marrow blast count &lt; 5 % neutrophil count &gt; 1000 cells/µL platelet count &gt; 100,000 cells/µL . OR morphological complete remission incomplete blood recovery ( CRi ) , i.e . bone marrow blast count &lt; 5 % neutrophil count &lt; 1000 cells/µL platelet count &lt; 100,000 cells/µL . For purpose study protocol , platelet count must &gt; 50,000 cells/µL . Interval completion last chemotherapy administration start vaccination ( start followup case control arm ) : 6 week ( minimum ) 16 week ( maximum ) . Age : &gt; 65 year time enrollment . WHO performance status : grade 0 1 time enrollment . For definition performance status , see : http : //www.ecog.org/general/perf_stat.html Absence psychological , familial , sociological , geographical physical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient study entry . Participation interventional clinical trial study period . History concomitant presence malignancy , except : nonmelanoma skin cancer carcinoma situ cervix effectively treat malignancy remission &gt; 5 year highly likely cured time enrollment . Concomitant presence immunosuppressive disease ( e.g . HIV ) active autoimmune condition , except vitiligo . Concomitant use systemic corticosteroid immunosuppressive dos ( &gt; 1 mg/kg/day prednisone , equivalent dose corticosteroid preparation ) immunosuppressive agent . A minimum 4 week must elapse last dose immunosuppressive therapy first vaccination . Topical corticosteroid permit , except apply site DC injection .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>complete remission</keyword>
	<keyword>old 65 year</keyword>
</DOC>